ERBB2 and osteosarcoma: As mentioned above, trastuzumab is the first and representative HER2-targeted antitumor agent, and it is the only HER2-targeted agent whose efficacy has been evaluated in prospective clinical trials for osteosarcoma prior to the advent of trastuzumab deruxtecan.